1. participant has clinical signs suggestive of moderate (pneumonia) or more severe illnesses with covid-19 (as defined in the taiwan cdc "interim guideline for clinical management of sars-cov-2 infection version 13" (taiwan cdc, clinical management of sars-cov-2 infection). 2. participation in any other clinical study of an investigational agent treatment for sars- cov-2 infection within 30 days prior to the first imp dosing. 3. participant who has a history of confirmed sars-cov-2 infection. 4. concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 \< 24 hours prior to the first imp dosing. 5. history of severe renal disease (treatment with dialysis or phosphate binders) or clinically apparent hepatic impairment (e.g., jaundice, cholestasis, hepatic synthetic impairment, active hepatitis). 6. impaired cardiac function or clinically significant cardiac diseases as judged by the investigator. 7. history of anaphylaxis reaction to any known or unknown cause. 8. immunosuppressed persons as result of illness (e.g., hiv infection) or treatment. 9. documented history of bell's palsy. 10. history of allergic reaction to kanamycin. 11. immunosuppressive treatment within 3 months prior to the screening visit. 12. ongoing treatment with any specific immunotherapy at the time of the screening visit. 13. assessed by the investigator to be ineligible to participate in the study.

1. participant has clinical signs suggestive of moderate (pneumonia) or more severe illnesses with covid-19 (as defined in the taiwan cdc "interim guideline for clinical management of sars-cov-2 infection version 13" (taiwan cdc, clinical management of sars-cov-2 infection). 2. participation in any other clinical study of an investigational agent treatment for sars- cov-2 infection within 30 days prior to the first imp dosing. 3. participant who has a history of confirmed sars-cov-2 infection. 4. concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 \< 24 hours prior to the first imp dosing. 5. history of severe renal disease (treatment with dialysis or phosphate binders) or clinically apparent hepatic impairment (e.g., jaundice, cholestasis, hepatic synthetic impairment, active hepatitis). 6. impaired cardiac function or clinically significant cardiac diseases as judged by the investigator. 7. history of anaphylaxis reaction to any known or unknown cause. 8. immunosuppressed persons as result of illness (e.g., hiv infection) or treatment. 9. documented history of bell's palsy. 10. history of allergic reaction to kanamycin. 11. immunosuppressive treatment within 3 months prior to the screening visit. 12. ongoing treatment with any specific immunotherapy at the time of the screening visit. 13. assessed by the investigator to be ineligible to participate in the study.

participant has clinical signs suggestive of moderate (pneumonia) or more severe illnesses with covid-19 (as defined in the taiwan cdc "interim guideline for clinical management of sars-cov-2 infection version 13" (taiwan cdc, clinical management of sars-cov-2 infection). participation in any other clinical study of an investigational agent treatment for sars- cov-2 infection within 30 days prior to the first imp dosing. participant who has a history of confirmed sars-cov-2 infection. concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 < 24 hours prior to the first imp dosing. history of severe renal disease (treatment with dialysis or phosphate binders) or clinically apparent hepatic impairment (e.g., jaundice, cholestasis, hepatic synthetic impairment, active hepatitis). impaired cardiac function or clinically significant cardiac diseases as judged by the investigator. history of anaphylaxis reaction to any known or unknown cause. immunosuppressed persons as result of illness (e.g., hiv infection) or treatment. documented history of bell's palsy. history of allergic reaction to kanamycin. immunosuppressive treatment within 3 months prior to the screening visit. ongoing treatment with any specific immunotherapy at the time of the screening visit. assessed by the investigator to be ineligible to participate in the study.

participant has clinical signs suggestive of moderate (pneumonia) or more severe illnesses with covid-19 (as defined in the taiwan cdc "interim guideline for clinical management of sars-cov-2 infection version 13" (taiwan cdc, clinical management of sars-cov-2 infection). participation in any other clinical study of an investigational agent treatment for sars- cov-2 infection within 30 days prior to the first imp dosing. participant who has a history of confirmed sars-cov-2 infection. concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 < 24 hours prior to the first imp dosing. history of severe renal disease (treatment with dialysis or phosphate binders) or clinically apparent hepatic impairment (e.g., jaundice, cholestasis, hepatic synthetic impairment, active hepatitis). impaired cardiac function or clinically significant cardiac diseases as judged by the investigator. history of anaphylaxis reaction to any known or unknown cause. immunosuppressed persons as result of illness (e.g., hiv infection) or treatment. documented history of bell's palsy. history of allergic reaction to kanamycin. immunosuppressive treatment within 3 months prior to the screening visit. ongoing treatment with any specific immunotherapy at the time of the screening visit. assessed by the investigator to be ineligible to participate in the study.

participant has clinical signs suggestive of moderate (pneumonia) or more severe illnesses with covid-19 (as defined in the taiwan cdc "interim guideline for clinical management of sars-cov-2 infection version 13" (taiwan cdc, clinical management of sars-cov-2 infection). participation in any other clinical study of an investigational agent treatment for sars- cov-2 infection within 30 days prior to the first imp dosing. participant who has a history of confirmed sars-cov-2 infection. participant has received an investigational or marketed covid-19 vaccine. concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 < 24 hours prior to the first imp dosing. history of severe renal disease (treatment with dialysis or phosphate binders) or clinically apparent hepatic impairment (e.g., jaundice, cholestasis, hepatic synthetic impairment, active hepatitis). impaired cardiac function or clinically significant cardiac diseases as judged by the investigator. history of anaphylaxis reaction to any known or unknown cause. immunosuppressed persons as result of illness (e.g., hiv infection) or treatment. documented history of bell's palsy. history of allergic reaction to kanamycin. immunosuppressive treatment within 3 months prior to the screening visit. ongoing treatment with any specific immunotherapy at the time of the screening visit. assessed by the investigator to be ineligible to participate in the study.

participant has clinical signs suggestive of moderate (pneumonia) or more severe illnesses with covid-19 (as defined in the taiwan cdc "interim guideline for clinical management of sars-cov-2 infection version 13" (taiwan cdc, clinical management of sars-cov-2 infection). participation in any other clinical study of an investigational agent treatment for sars- cov-2 infection within 30 days prior to the first imp dosing. participant who has a history of confirmed sars-cov-2 infection. participant has received an investigational or marketed covid-19 vaccine. concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 < 24 hours prior to the first imp dosing. history of severe renal disease (treatment with dialysis or phosphate binders) or clinically apparent hepatic impairment (e.g., jaundice, cholestasis, hepatic synthetic impairment, active hepatitis). impaired cardiac function or clinically significant cardiac diseases as judged by the investigator. history of anaphylaxis reaction to any known or unknown cause. immunosuppressed persons as result of illness (e.g., hiv infection) or treatment. documented history of bell's palsy. history of allergic reaction to kanamycin. immunosuppressive treatment within 3 months prior to the screening visit. ongoing treatment with any specific immunotherapy at the time of the screening visit. assessed by the investigator to be ineligible to participate in the study.

1. participant has clinical signs suggestive of moderate (pneumonia) or more severe illnesses with covid-19 (as defined in the taiwan cdc "interim guideline for clinical management of sars-cov-2 infection version 13" (taiwan cdc, clinical management of sars-cov-2 infection). 2. participation in any other clinical study of an investigational agent treatment for sars- cov-2 infection within 30 days prior to the first imp dosing. 3. participant who has a history of confirmed sars-cov-2 infection. 4. participant has received an investigational or marketed covid-19 vaccine. 5. concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 < 24 hours prior to the first imp dosing. 6. history of severe renal disease (treatment with dialysis or phosphate binders) or clinically apparent hepatic impairment (e.g., jaundice, cholestasis, hepatic synthetic impairment, active hepatitis). 7. impaired cardiac function or clinically significant cardiac diseases as judged by the investigator. 8. history of anaphylaxis reaction to any known or unknown cause. 9. immunosuppressed persons as result of illness (e.g., hiv infection) or treatment. 10. documented history of bell's palsy. 11. history of allergic reaction to kanamycin. 12. immunosuppressive treatment within 3 months prior to the screening visit. 13. ongoing treatment with any specific immunotherapy at the time of the screening visit. 14. assessed by the investigator to be ineligible to participate in the study.

1. participant has clinical signs suggestive of moderate (pneumonia) or more severe illnesses with covid-19 (as defined in the taiwan cdc "interim guideline for clinical management of sars-cov-2 infection version 13" (taiwan cdc, clinical management of sars-cov-2 infection). 2. participation in any other clinical study of an investigational agent treatment for sars- cov-2 infection within 30 days prior to the first imp dosing. 3. participant who has a history of confirmed sars-cov-2 infection. 4. participant has received an investigational or marketed covid-19 vaccine. 5. concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 < 24 hours prior to the first imp dosing. 6. history of severe renal disease (treatment with dialysis or phosphate binders) or clinically apparent hepatic impairment (e.g., jaundice, cholestasis, hepatic synthetic impairment, active hepatitis). 7. impaired cardiac function or clinically significant cardiac diseases as judged by the investigator. 8. history of anaphylaxis reaction to any known or unknown cause. 9. immunosuppressed persons as result of illness (e.g., hiv infection) or treatment. 10. documented history of bell's palsy. 11. history of allergic reaction to kanamycin. 12. immunosuppressive treatment within 3 months prior to the screening visit. 13. ongoing treatment with any specific immunotherapy at the time of the screening visit. 14. assessed by the investigator to be ineligible to participate in the study.